Choosing Stock Market Today Is Simple
Jun0
The stock market is very unpredictable today more than ever. Lots of investors really got burned for the last few years as the market spinned into recession and that makes them hopeless.
Since nobody can tell and predict the future of the market, so all kinds of stocks values are always based on past histories
For quite sometimes it can be quite accurate, however when it comes to the short term predicting the stock market changes is almost impossible to get 100% accuracy.
Investors really have to know something on human psychology to really understand what may happen in the market. Many always overly optimistic when the market is good and then they start to become greedy.
Here are some things you should know about the stock market today:
- Many top investors like Warren Buffet have invested seriously in the market using their own money, that signs indicate that the market is at the bottom for this recession. Even the popular Canadian stock exchange also at the bottom in this recession.
- You will miss the biggest opportunities if you wait until things have already turned around to buy in, since 80 percents of the gains for depressed stocks come in the first year of recovery.
- The stock market today is filled with lots of companies that are under funded by pension plans and have huge hidden debts.
With such massive losses so clear in the memory, the stock market today can seem a terrible place. But indeed, the thing that you should be worried about is actually waiting to long to be able to get back in.
Lots of opportunities in the market right now. It’s only requires a lot of studying on your part, to make sure that every investments you place are with the companies that have strenght and are well. And the last but not least, it is also very important you take the time to learn about how does the stock market work before you get started.
Mail this postPopularity: 14% [?]
Potential Bargains Among Small Biotech Stocks
Apr0
The steeply declining markets of the past year have produced many undervalued stocks that perceptive investors can take potentially highly rewarding positions in. Some fo the more attractive opportunities exist in the price-depressed stocks of biotech companies with promising technologies and good clinical prospects.
Avoiding single product risk is an important consideration in selecting investments in small biotech companies that are not yet profitable. Avoid allocating too high a percentage of your risk capital to companies who are dependent on the results of single products that are still in clinical trials. While big breakthroughs are possible for single-product companies, there are also many failures along the way; in these tough economic times, there will be little sympathy given by the financial world to product failures. It is far better to choose companies with strong technology that can be applied to multiple opportunities.
An interesting company that appears to be dramatically undervalued is iBioPharma, Inc. Spun off from an older parent company with no desire to pursue biotech research, this company came into existence at the beginning of the current global financial meltdown. Its relative obscurity coupled with virtually all stock prices dropping has created an interesting value proposition for investors. Trading under the symbol IBPM, the company has proprietary technology for vaccine production which can be applied to a number of different diseases. Among the possibilities are pandemic influenza, anthrax and human papilloma virus vaccines. Substantial funding has already been committed by the U.S. government and by the Bill & Melinda Gates Foundation.
Another company to consider is GenVec, Inc. This company has developed technology for gene-based therapeutic drugs applicable to a number of diseases including cancer, age-related macular degeneration, and certain infectious diseases. Trading under the symbol GNVC, the company’s most advanced product is for advanced pancreatic cancer therapy and is in a pivotal clinical trial. The company has made significant technical progress, but its stock price has been driven down over the past nine months by general market forces.
For bold investors looking for rare bargains, this could be just the right time. With a little research and a little luck, investment returns on well-chosen, low-priced biotech stocks could be a good personal antidote to the ailing economy. This article’s author does not own stock in either of the companies discussed herein. This information is for educational purposes only and is not a recommendation to buy or sell any specific securities.
Mail this postPopularity: 11% [?]
